It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Liver failure causes breakdown of the Blood CNS Barrier (BCB) leading to damages of the Central-Nervous-System (CNS), however the mechanisms whereby the liver influences BCB-integrity remain elusive. One possibility is that the liver secretes an as-yet to be identified molecule(s) that circulate in the serum to directly promote BCB-integrity. To study BCB-integrity, we developed light-sheet imaging for three-dimensional analysis. We show that liver- or muscle-specific knockout of Hfe2/Rgmc induces BCB-breakdown, leading to accumulation of toxic-blood-derived fibrinogen in the brain, lower cortical neuron numbers, and behavioral deficits in mice. Soluble HFE2 competes with its homologue RGMa for binding to Neogenin, thereby blocking RGMa-induced downregulation of PDGF-B and Claudin-5 in endothelial cells, triggering BCB-disruption. HFE2 administration in female mice with experimental autoimmune encephalomyelitis, a model for multiple sclerosis, prevented paralysis and immune cell infiltration by inhibiting RGMa-mediated BCB alteration. This study has implications for the pathogenesis and potential treatment of diseases associated with BCB-dysfunction.
Blood vessel integrity is critical to maintain brain health. Here, the authors show that both the liver and the muscles secrete HFE2, a protein that promotes blood vessel integrity in healthy animals and in an animal model for multiple sclerosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 University Health Network, Krembil Discovery Tower, Krembil Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Institute of Biomedical and Biomaterial Engineering, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 University Health Network, Krembil Discovery Tower, Krembil Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Department of Physiology, Faculty of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
3 University Health Network, Krembil Discovery Tower, Krembil Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
4 Keck School of Medicine of the University of Southern California, Department of Physiology and Neuroscience, The Zilkha Neurogenetic Institute, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
5 University of Maryland, School of Medicine, Department of Neurology, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)
6 University Health Network, Toronto General Hospital Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
7 BioNTech resano GmbH, Mainz, Germany (GRID:grid.17063.33)
8 University Health Network, Krembil Discovery Tower, Krembil Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University and University Hospital Zurich, Group of CNS Angiogenesis and Neurovascular Link, and Physician-Scientist Program, Institute for Regenerative Medicine, Neuroscience Center Zurich, and Division of Neurosurgery, Zurich, Switzerland (GRID:grid.412004.3) (ISNI:0000 0004 0478 9977); University Hospital Zurich, Division of Neurosurgery, Zurich, Switzerland (GRID:grid.412004.3) (ISNI:0000 0004 0478 9977); University Health Network, Division of Neurosurgery, Department of Surgery, Toronto Western Hospital, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428)
9 The Neuro - Montreal Neurological Institute and Hospital, Montréal, Canada (GRID:grid.416102.0) (ISNI:0000 0004 0646 3639)
10 University Health Network, Krembil Discovery Tower, Krembil Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Institute of Biomedical and Biomaterial Engineering, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Keck School of Medicine of the University of Southern California, Department of Physiology and Neuroscience, The Zilkha Neurogenetic Institute, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
11 University Health Network, Krembil Discovery Tower, Krembil Research Institute, Toronto, Canada (GRID:grid.231844.8) (ISNI:0000 0004 0474 0428); University of Toronto, Institute of Biomedical and Biomaterial Engineering, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Ophthalmology and Vision Sciences, Faculty of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)